These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 26614030)

  • 1. Pharmacogenomics: Biomarker-Directed Therapy for Bladder Cancer.
    Jones RT; Felsenstein KM; Theodorescu D
    Urol Clin North Am; 2016 Feb; 43(1):77-86. PubMed ID: 26614030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Waiting in the wings: the emerging role of molecular biomarkers in bladder cancer.
    Ilijazi D; Abufaraj M; Hassler MR; Ertl IE; D'Andrea D; Shariat SF
    Expert Rev Mol Diagn; 2018 Apr; 18(4):347-356. PubMed ID: 29542328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A precision, personalized approach to the management of bladder cancer.
    Apolo AB; Burger M
    Curr Opin Urol; 2015 Sep; 25(5):416-7. PubMed ID: 26153639
    [No Abstract]   [Full Text] [Related]  

  • 4. Molecular biomarkers in bladder preservation therapy for muscle-invasive bladder cancer.
    Miyamoto DT; Mouw KW; Feng FY; Shipley WU; Efstathiou JA
    Lancet Oncol; 2018 Dec; 19(12):e683-e695. PubMed ID: 30507435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenetics and pharmacogenomics as tools in cancer therapy.
    Rodríguez-Vicente AE; Lumbreras E; Hernández JM; Martín M; Calles A; Otín CL; Algarra SM; Páez D; Taron M
    Drug Metab Pers Ther; 2016 Mar; 31(1):25-34. PubMed ID: 26863347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic subtypes of invasive bladder cancer.
    McConkey DJ; Choi W; Dinney CP
    Curr Opin Urol; 2015 Sep; 25(5):449-58. PubMed ID: 26218634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Developing Precision Medicine for Bladder Cancer.
    Guercio BJ; Iyer G; Rosenberg JE
    Hematol Oncol Clin North Am; 2021 Jun; 35(3):633-653. PubMed ID: 33958155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. National Comprehensive Cancer Network Recommendations on Molecular Profiling of Advanced Bladder Cancer.
    Pal SK; Agarwal N; Boorjian SA; Hahn NM; Siefker-Radtke AO; Clark PE; Plimack ER
    J Clin Oncol; 2016 Sep; 34(27):3346-8. PubMed ID: 27458279
    [No Abstract]   [Full Text] [Related]  

  • 9. Genomic profiling guides the choice of molecular targeted therapy of pancreatic cancer.
    Frank TS; Sun X; Zhang Y; Yang J; Fisher WE; Gingras MC; Li M
    Cancer Lett; 2015 Jul; 363(1):1-6. PubMed ID: 25890222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Emergence of Precision Urologic Oncology: A Collaborative Review on Biomarker-driven Therapeutics.
    Barbieri CE; Chinnaiyan AM; Lerner SP; Swanton C; Rubin MA
    Eur Urol; 2017 Feb; 71(2):237-246. PubMed ID: 27567210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging Bladder Cancer Biomarkers and Targets of Therapy.
    Netto GJ; Tafe LJ
    Urol Clin North Am; 2016 Feb; 43(1):63-76. PubMed ID: 26614029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacogenomic biomarkers for personalized cancer treatment.
    Rodríguez-Antona C; Taron M
    J Intern Med; 2015 Feb; 277(2):201-217. PubMed ID: 25338550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Precision medicine for urothelial bladder cancer: update on tumour genomics and immunotherapy.
    Felsenstein KM; Theodorescu D
    Nat Rev Urol; 2018 Feb; 15(2):92-111. PubMed ID: 29133939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toward personalized management in bladder cancer: the promise of novel molecular taxonomy.
    Eich ML; Dyrskjøt L; Netto GJ
    Virchows Arch; 2017 Aug; 471(2):271-280. PubMed ID: 28429075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ERBB2 Mutations Characterize a Subgroup of Muscle-invasive Bladder Cancers with Excellent Response to Neoadjuvant Chemotherapy.
    Groenendijk FH; de Jong J; Fransen van de Putte EE; Michaut M; Schlicker A; Peters D; Velds A; Nieuwland M; van den Heuvel MM; Kerkhoven RM; Wessels LF; Broeks A; van Rhijn BW; Bernards R; van der Heijden MS
    Eur Urol; 2016 Mar; 69(3):384-8. PubMed ID: 25636205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. From Detection to Cure - Emerging Roles for Urinary Tumor DNA (utDNA) in Bladder Cancer.
    Linscott JA; Miyagi H; Murthy PB; Yao S; Grass GD; Vosoughi A; Xu H; Wang X; Yu X; Yu A; Zemp L; Gilbert SM; Poch MA; Sexton WJ; Spiess PE; Li R
    Curr Oncol Rep; 2024 Aug; 26(8):945-958. PubMed ID: 38837106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biomarkers for precision medicine in bladder cancer.
    Kojima T; Kawai K; Miyazaki J; Nishiyama H
    Int J Clin Oncol; 2017 Apr; 22(2):207-213. PubMed ID: 27896485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacogenomics in bladder cancer.
    Dancik GM; Theodorescu D
    Urol Oncol; 2014 Jan; 32(1):16-22. PubMed ID: 24360659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant therapy in muscle-invasive bladder cancer: a model for rational accelerated drug development.
    Balar AV; Milowsky MI
    Urol Clin North Am; 2015 May; 42(2):217-24, viii-ix. PubMed ID: 25882563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Individualized management of advanced bladder cancer: Where do we stand?
    Burgess EF
    Urol Oncol; 2015 Apr; 33(4):187-95. PubMed ID: 24332641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.